In chronic GVHD after BMT, the conjunctiva represents a target organ. GVHD can lead to severe inflammation and dry-eye syndrome (sicca syndrome). The molecular mechanisms are largely unknown. We examined the expression of chemokines in the conjunctiva in cases of chronic GVHD. In this study, we included 10 patients with chronic GVHD and 10 healthy controls. Clinical data were collected and tear film analysis and conjunctival cytology were carried out. Conjunctival biopsies were taken from all participants. Gene expression profiles of chemokines and their corresponding receptors were evaluated by means of quantitative real-time PCR. Chemokine protein expression was analysed by immunohistochemical analyses. Expressions of the Th1-associated chemokines, chemokine (C-X-C motif) ligand (CXCL) 9 (Mig), CXCL10 (IP-10), and their receptor chemokine (C-X-C motif) receptor 3 (CXCR3) were significantly increased in GVHD patients. Immunohistochemical analysis confirmed marked expression of the inflammatory CXCR3 ligands. A total of six patients had a moderate or severe sicca syndrome. Impression cytology revealed a mild keratinisation, moderate keratinisation or severe squamous metaplasia in three patients, respectively. Chronic GVHD of the conjunctiva is characterised by the expression of Th1-associated chemokines. Taken together, our results confirm that the conjunctiva is a target organ in this T cell-mediated process and add to molecular understanding of conjunctival GVHD.
Introduction
Despite HLA typing, the incidence of GVHD after allogeneic haematopoietic stem cell transplantation (HSCT) is about 30-50%.
1,2 The current understanding of chronic GVHD defines it as an overlap syndrome with features of both the acute and chronic form, but also includes the classic, time-dependent definition of chronic GVHD. 3 In contrast to the acute GVHD, the chronic form is rather a disseminated multi-organ disease in which the ocular surface has been recognised as a target organ. [4] [5] [6] Ocular surface effects in chronic GVHD most often result in a severe dry-eye syndrome (sicca syndrome) with loss of the ocular surface integrity. The symptoms and complications can reduce the quality of life dramatically and even threaten vision. [7] [8] [9] [10] [11] Ocular involvement seems to correlate to the severity of the GVHD. 4, 5 Activated donor T cells have been identified as the major effectors in the pathogenesis of the GVHD. 1, 12 T cells maintain and amplify the conjunctival inflammation through the release of effector cytokines, such as IFN-g 13 and subsequently lead to tissue destruction, 1, 14 here on the ocular surface.
Chemokines are small, secreted proteins that have been shown to mediate directed T cell migration and critically regulate organ-specific homing of leukocytes. [15] [16] [17] [18] In ocular surface diseases, chemokines have an important role in inflammatory processes occurring in vernal keratoconjunctivitis 19, 20 and atopic conjunctivitis. 21, 22 Moreover, studies have demonstrated that corneal epithelial and stromal cells are capable of producing various chemokines in herpetic stromal keratitis and inflamed corneas after perforating injuries. 23, 24 It has been demonstrated that members of the chemokine superfamily are involved in immunological and autoimmunological diseases. [25] [26] [27] The upregulation of several chemokines is associated with acute GVHD. 28, 29 However, the pathogenic role of chemokines in chronic conjunctival GVHD remains elusive to a large extent.
Until now there have been few data to show the involvement of chemokines and their receptors in the pathogenesis of conjunctival chronic GVHD. In this study, we analysed the chemokine gene and protein expression pattern in the conjunctiva of patients suffering from chronic GVHD. Using quantitative real-time PCR, we found significantly elevated levels of pro-inflammatory chemokines in the conjunctiva of patients with chronic GVHD compared with healthy controls. These findings were confirmed by immunohistochemistry using monoclonal antibodies against different chemokines and their respective receptors in conjunctival biopsies of patients with chronic GVHD compared with healthy controls.
Materials and methods

Patients
The study has been approved by the appropriate local ethics committee and followed the tenets of the Declaration of Helsinki. In this study, 10 patients who suffered from chronic GVHD after HSCT were investigated. The grading of GVHD followed the 'Consensus Conference in Acute GVHD Grading' 30 and the grading system of Gratwohl et al. 31 for chronic GVHD. As a control group, we included 10 patients who visited our clinic for cataract or strabismus surgery. All patients signed an informed consent form and underwent clinical examination to detect dry-eye-associated ocular surface changes. A conjunctival biopsy was performed under local anaesthesia from all patients from the bulbar conjunctiva, quickly frozen in liquid nitrogen and stored at À80 1C until analysis. The biopsies were used to perform quantitative real-time PCR analysis and immunohistochemistry.
Clinical examination
Clinical examination routinely included best-corrected visual acuity, intraocular pressure, slit-lamp examination of the anterior segment and funduscopy of the retina. Dryeye syndrome related examination included Schirmer test (basal tear secretion), fluorescein clearance test, vital staining with fluorescein (50 ml fluorescein-Na 1%) and Rose Bengal (50 ml Rose Bengal 0.5%), tear film break-up time, Meibomian gland status and impression cytology (IPC) of the conjunctiva.
Vital staining of the corneal surface reveals epithelial defects, including erosion or punctuate erosions and late fluorescein staining in case of vascularisation of the cornea.
For the fluorescein clearance test, 10 ml of fluorescein Na 1% was applied to the conjunctival surface. The fluorescein clearance test gives information about the basal and stimulated aqueous tear secretion and about the fluorescein clearance from the ocular surface. A continuous staining reflected a 'delayed tear clearance'. 32, 33 The Meibomian gland status was tested by transpalpebral illumination and graded into three groups. Grade 1 reflected a Meibomian gland atrophy in less than one-third of the eye lid, grade 2 an atrophy of no more than twothirds and grade 3 a Meibomian gland atrophy of more than two-thirds of the eye lid. 34 The IPC was performed using 4 Â 7 mm filtration paper that was pressed gently on the conjunctival surface under local anaesthesia. The collected specimen were fixated in formalin (3.7%) and stained with periodic acid-Schiffhaematoxylin staining. The IPC was used to detect dry-eye associated morphological changes in the conjunctival epithelium, such as loss of goblet cells, cellular desquamation resulting in squamous metaplasia. We applied the grading system according to Koch et al.
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A pathological tear film break-up time points to a lipid tear deficiency on the ocular surface, whereas a pathological Schirmer test (basal tear secretion) points to an aqueous tear deficiency. Often, both occur. The meibomian gland affection, the vital staining and the clearance reduction were graded in relation to the intensity of the pathological changes. These tests specify the extent of the fluid-or lipid-deficiency syndrome and together with the results of the IPC they sum up to the grade of the sicca syndrome.
Quantitative real-time PCR analysis Quantitative real-time PCR analyses were performed as previously described. 27,36. Conjunctival biopsy specimens were homogenised in liquid nitrogen using a MicroDismembrator U (Braun Biotech, San Diego, CA, USA), and RNA was extracted with RNAzol according to the manufacturer's protocol (Tel-Test, Friedensburg, TX, USA). A total of 4 mg of RNA was treated with DNase I (Boehringer, Mannheim, Germany) and reverse transcribed with oligo(dT)14-18 (Gibco BRL, Gaithersburg, MD, USA) and random hexamer primers (Promega, Madison, WI, USA), using standard protocols. A total of 25 ng of complementary DNA was amplified in the presence of 12.5 ml of TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 0.625 ml of genespecific TaqMan probe, 0.5 ml of gene-specific forward and reverse primers, and 0.5 ml of water. Chemokine ligand-and chemokine receptor-specific primers and target-specific probes were obtained from Applied Biosystems. In the first step, a chemokine-expression screening was performed on the following selected chemokines: chemokine (C-C motif) ligand (CCL) 1 (I-309), CCL2 (MCP-1), CCL17 (TARC), CCL18 (PARC), CCL27 (CTACK), chemokine (C-X-C motif) ligand (CXCL) 9, CXCL10, CXCL11 and the receptors chemokine (C-C motif) receptor (CCR) 2, chemokine (C-X-C motif) receptor (CXCR) 3 and CXCR4. This was done to identify interesting target chemokines using only a set of five probes from patients and controls. Afterwards CXCL9, CXCL10 and CXCL11, as well as their receptor CXCR3 were analysed in all probes. Genespecific PCR products were measured with an ABI PRISM 7700 or 5700 Sequence Detection System (Applied Biosystems), continuously during 40 cycles. Target gene expression was normalised between different samples on the basis of the expression values of the internal positive control (18S RNA) or ubiquitin. 27, 36 Immunohistochemistry For immunohistochemical analysis of the expression of chemokines and chemokine receptors, conjunctival sections were fixed with acetone and pre-processed with H 2 O 2 followed by an avidin-biotin blocking step (Avidin/Biotin Blocking Kit; Vector, Burlingame, CA, USA). Sections were stained with monoclonal antibodies against CXCR3 (mouse IgG1; R&D Systems, Minneapolis, MN, USA), CXCR4 (mouse IgG2b; R&D Systems), CXCL9 (goat IgG; R&D Systems), CXCL10 (goat IgG; R&D Systems) and CXCL12 (mouse IgG2a, K15C; Unite 0 d'Immunologie Virale, Institute Pasteur, Paris, France). CXCL12 served as positive control as it is a homeostatic chemokine and was therefore expected to be present in patients as well as controls. For each antibody, an appropriate isotype control (all R&D Systems) was stained. Development of the staining was performed using a Vectastain ABC kit and a Vectastain AEC kit (both from Vector). Sections were counterstained with haematoxylin.
Statistical analysis
Statistical analysis was performed using Microsoft Excel 2000 and Stat View for Windows (Abacus Concepts, Berkeley, CA, USA, Version 4.55). When calculating correlations, a P-value p0.05 was considered statistically significant. Spearman correlation and unpaired t-test were performed to test associations between chemokine gene expression and clinical findings or ocular complications.
Results
Demographic data
The mean age at the time of SCT was 42.07±9.49 years (median: 41.3, range: 30.9-59.8 years). The mean age at the time of study examination was 46.0 ± 10.4 years in the patients' group (median: 43.2, range: 34.8-63.6 years) and 70.8 ± 13.7 years in the control group (median: 75.4, range: 39.0-88.4 years). Interval-time between HSCT and the study examination was 48.28±31.61 months (median: 44.4, range: 9.3-109.0 months). All patients underwent allogeneic PBSCT. In four cases, the patients received PBSCT because of AML, in four cases because of CML. One patient suffered from ALL and another from a myelodysplastic syndrome. The conditioning regimen before SCT included TBI (10 Gy) and high-dose CY treatment in eight cases, TBI and fludarabin treatment in one case, and BU combined with high-dose CY treatment in one case. The GVHD prophylaxis was performed by MTX and CYA in eight cases, CYA alone in one case and CYA with mycophenolate mofetil in another. The analysis of the donor-host relation data revealed nine HLA-identical matches, one partially matched pair and eight pairs were gender matched. In six cases, the donor was unrelated to the recipient, in two cases the sister was the donor, in one case each the brother and the cousin. At the time of the study examination, all patients were in complete remission. Three patients did not receive any systemic immunosuppression at the time of examination. Two of them had received a transplant from an HLA-identical unrelated donor and one from a related donor (cousin). All three donors were male.
Ocular surface examinations
Mean time between SCT and the onset of dry-eye symptoms was 10.9 ± 3. 97 months (median: 10.3, range: 9.0-18.3 months). The results of ocular surface diagnostics and gradings are provided in Table 1 . A total of seven patients had a 'Delayed Tear Clearance' in the fluorescein clearance test. The results of the IPC are presented in Table 2 . Ocular surface complications during follow-up included corneal ulcers in four cases (two perforating ulcers), limbal stem cell deficiency with ingrowths of 
Chemokine gene expression
To investigate whether chemokines are involved in lymphocyte recruitment in conjunctival chronic GVHD, we performed quantitative real-time PCR analysis and demonstrated that the Th1-associated chemokines CXCL9, CXCL10, CXCL11 and their shared receptor CXCR3 were markedly upregulated in conjunctival chronic GVHD compared with healthy controls. The levels of CXCL9 (P ¼ 0.007) and CXCL10 (P ¼ 0.007), as well as the corresponding CXCR3 (P ¼ 0.049) showed a statistically significant difference between both groups (Figure 1 ). We found no significant difference in the expression of the chemokines CCL1, CCL2, CXCL12 and the receptor CXCR4. Although a trend toward increased expression of CCL17, CCL18 and CCL27, as well as CCR2 was observed, statistical analysis did not demonstrate a significant up regulation of these genes in conjunctival chronic GVHD.
Immunohistochemistry of chemokines CXCL9, CXCL10, CXCL11 and CXCR3
To identify the cellular origin and obtain insights into the anatomic location of CXCL9, CXCL10 and CXCL11 and their receptor CXCR3 within the conjunctiva, we performed immunohistochemical analyses (Figures 2, 3) . CXCL9, CXCL10 and CXCR3 were expressed to a higher extent in the patient group than in the controls. Within the conjunctiva, cells with dendritic morphology as well as endothelial cells of the superficial stromal conjunctiva were identified as abundant sources of CXCL9 expression (Figures 2a and b) . In contrast, CXCL10 showed marked expression in all layers of the conjunctival epithelium in the patient's group but was almost negative in the controls (Figures 2c and d) . Their receptor, CXCR3, demonstrated strong expression on conjunctivainfiltrating leukocytes in perivascular, stromal locations of GVHD patients (Figures 3a and b) . Endothelial cells also showed strong staining for CXCR3 (Figures 3a  and b) . The homeostatic chemokine CXCL12 was positive in both groups and was observed in the basal epithelium, in endothelial cells and conjunctiva-infiltrating leukocytes (Figures 3c and d) . The corresponding receptor, CXCR4, was expressed by conjunctiva-infiltrating leukocytes (Figures 3e and f The T-lines below and above the box mark the 10th percentile (below) and the 90th percentile (above). CXCL11 expression revealed a trend towards a higher expression in the GVHD group, although the statistical result was not quite significant.
Association of chemokine gene expression to clinical findings and ocular complications
Statistical analysis did not reveal a correlation between any of the chemokines CXCL9-11 and their receptor CXCR3 and the following factors: sicca grade, basal tear secretion, tear film break-up time, vital staining of ocular surface, tear clearance reduction, Meibomian gland effects, IPC, ocular complications, age at HSCT, gender of donor, relation donor to recipient, HLA match, conditioning regime, GVHD prophylaxis and interval from HSCT to occurrence of dryeye syndrome. The P-values of Spearman's correlation and unpaired t-test lay between P ¼ 0.08 and P ¼ 0.93 (data not shown).
Discussion
Chemokines represent a superfamily of small cytokine-like proteins that mediate directional migration in vitro and control leukocyte trafficking in vivo.
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In this study, we demonstrate the induction of a distinct panel of genes and proteins in the conjunctiva of patients suffering from chronic GVHD. Notably, the Th1-associated chemokines CXCL9, CXCL10 and CXCL11, as well as their receptor CXCR3 were the most upregulated chemokine ligands and receptors in chronic conjunctival GVHD compared with healthy controls. Although these chemokines are not specific for chronic GVHD, quantitative monitoring of the gene expression of chemokines and their receptors may be a valuable molecular method to monitor and diagnose chronic GVHD of the conjunctiva. Testing on other chemokines (CCL1, CCL2, CCL17, CCL18 and CCL27) and chemokine receptors (CCR2 and CXCR4) revealed no differential expression between patients with chronic GVHD and controls. In this pilot study, healthy persons were chosen as controls. In a limited cohort as we present in this study, we preferred the comparison with normal tissue rather than with tissue that might be affected by non-immunological factors, such as myeloablative therapy before HSCT in patients that received HSCT and did not develop GVHD. The difference in the mean age between patients and controls was accepted because the functional analysis of the ocular surface did not reveal any pathological changes in the control group.
A hallmark of chronic GVHD is the expression of IFNg, even though the pathogenetic importance is controversial. 37 Interferon-g is a potent inducer for the expression of the CXCR3 ligands, CXCL9, CXCL10 and CXCL11 (I-TAC). 38, 39 Among the memory T cell subsets, CXCR3 is predominantly expressed on the surface of IFN-gproducing Th1 cells. 18 The findings in this study demon- ; (e and f) CXCR4. CXCR3 is expressed in the conjunctival stroma and perivascular endothelium (arrows). CXCL12 is positively expressed in both groups and is markedly shown in the basal epithelium-, endothelium-and conjunctiva-infiltrating leucocytes (arrows). Conjunctiva-infiltrating leucocytes also express CXCR4 (arrows).
strate that the majority of cells infiltrating the conjunctiva display CXCR3 on their cell surface. Recent studies have shown by gene expression profiling that pro-inflammatory chemokines are upregulated in different target organs of GVHD. 28, 29, 40 In addition, the influence of chemokines on the recruitment of activated CD4 þ T cells into the skin of GVHD patients has been elucidated. 41 Supporting these data, another study found an elevated expression of CXCL10 in the epidermis and also higher levels of its receptor CXCR3 in dermal inflammatory infiltrates of patients suffering from GVHD.
14 Moreover, Zhou et al. 42 demonstrated that CXCL9, CXCL10 and CXCL11 are upregulated in the skin of an experimental murine model with sclerodermatous GVHD. Our findings are in line with these reports and indicate that CXCL9 and CXCL10 have a central role in the pathogenesis of conjunctival chronic GVHD by the recruitment of CXCR3 þ T cells to the sites of inflammation.
Synergistic cooperation between inflammatory and homeostatic chemokines has been shown to promote the recruitment of leukocytes. In particular, the inflammatory chemokine CXCL10 primed T cells to migrate to suboptimal doses of the homeostatic chemokine CXCL12. On the basis of this information, we observed that the expression of CXCR3 ligands as well as that of CXCL12 in close anatomic proximity to cells expressing their matching receptors CXCR3 and CXCR4 were of great importance. One explanation is that these chemokines are also cooperating in chronic GVHD and cause the migration of effector T cells into the conjunctiva. Within the conjunctiva, activated T cells may release effector cytokines such as IFN-g. In turn, IFN-g strengthened the expression of CXCR3 ligands leading to an enhanced migration of T cells and the amplification of the inflammatory reaction.
Selective inhibition of chemokine production or specific antagonisms of chemokine receptors effectively prevent the development of GVHD. Studies underline the crucial role of chemokines in the pathogenesis of GVHD 43, 44 and provide the basis for alternative targeting therapies in GVHD.
We could not find a correlation between elevated chemokine expression and clinical findings concerning the conjunctival GVHD, the dry-eye symptoms and the HSCT-related factors. Furthermore, the ocular complications were not statistically correlated to the chemokine profile. This may be due to the low number of samples in our cohort or due to the heterogeneity of the patients. We are aware that this study is a retrospective pilot study but we have the intention to define new targets for further prospective investigations with a larger population of patients.
In summary, our study demonstrates, to the best of knowledge, for the first time a differential expression of a panel of chemokines and their respective receptors in chronic GVHD of the conjunctiva. It contributes to an improved molecular understanding of local inflammatory and immune processes occurring in chronic conjunctival GVHD. This study might be a first step to develop alternative monitoring techniques and targeted therapies for the vision-threatening ocular complications in chronic GVHD.
